KYGEVVI
Nov 10, 2025
UCB’s KYGEVVI Approval: A Breakthrough for Thymidine Kinase 2 Deficiency
In a significant milestone for the rare disease community, the FDA approved KYGEVVI (doxecitine and doxribtimine) in November 2025, marking the first and only approved treatment for thymidine kinase 2 deficiency (TK2d). This breakthrough approval represents a transformative moment for patients and families facing t...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
